We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
DIASOURCE (A Biovendor Company)

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App




New Test Diagnoses C. difficile with One Assay and No Retesting

By LabMedica International staff writers
Posted on 23 Feb 2015
A new CE-IVD certified molecular test provides rapid, accurate, single-test detection of toxigenic Clostridium difficile without the need for confirmatory retesting.

Greiner Bio-One International GmbH (Frickenhause, Germany, and Kremsmünster, Austria) has now added the Genspeed C.diff OneStep assay to its growing portfolio of CE-IVD certified molecular diagnostic tests for nosocomial infections. More...
Genspeed C.diff OneStep identifies toxigenic C. difficile by combining detection of 4 biomarkers: glutamatdehydrogenase (GDH), Toxin A, Toxin B, binary toxin in a single test. Complete analysis takes under 100 min (depending on PCR-cycler used), including detection on the Genspeed R2 Analyzer.

Genspeed C.diff OneStep’s new “1-test – 4-results” procedure avoids the currently used sequential 2-step procedures that combine different test systems and assay principles for GDH and the C. difficile toxins. It also provides conclusive results without the need for confirmatory re-testing and enables inter-laboratory comparisons of results.

Ready-to-use reagents and automated dispensing minimize the number of manual processing steps within the workflow. The Genspeed R2 Analyzer represents a reliable solution that is virtually service-free system, simple to operate, and available at an attractive cost-benefit ratio.

The new test addresses one of the most serious threats worldwide as C. difficile causes one of the most common serious healthcare system associated infections. In a 2013 report, the USA Center for Disease Control (CDC) categorized C. difficile infections as “Threat Level Urgent,” the highest level available.

All Genspeed products are currently available for sale in the EU and EFTA countries only.

Related Links:

Greiner Bio-One 
Genspeed Analyzer and Assays
Genspeed C.diff OneStep, assay brochure


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.